Navigation Links
Glazer receives grant to study light-activated cancer drugs
Date:1/31/2013

LEXINGTON, Ky. (Jan. 31, 2013) University of Kentucky assistant professor of chemistry Edith "Phoebe" Glazer has received an American Cancer Society Research Scholar Grant for $715,000 over four years to continue her research into ruthenium-based cancer drugs. These compounds are less toxic to healthy cells than a similar and widely used inorganic drug.

Cisplatin is a common platinum-based cancer drug used in a variety of cancer treatments. But while cisplatin kills cancer cells, it also attacks healthy cells, causing debilitating side effects. Ruthenium is another transition metal and belongs to the same group of the periodic table as iron.

Previously, the Glazer group developed two new ruthenium complexes designed to kill cancer cells while preserving healthy cells. These complexes are inert in the dark, but when activated with light, they become up to 200 times as toxic, and up to three times as potent as cisplatin against tumor cells.

Funded by the American Cancer Society, the new grant will allow Glazer's team to develop improved ruthenium-based compounds and to study their effectiveness. Using the strategy of combining organic ligands as building blocks that assemble around the ruthenium center "core," a large family of compounds with different structures and properties can be rapidly synthesized. This is in marked contrast to approaches using compounds discovered in nature, called natural products, as chemotherapeutics.

Many chemotherapeutics are natural products, but their synthesis is challenging and there are limited chemical modifications that can be made into the molecules. In the ruthenium compounds, the organic components can be easily changed to alter chemical properties and possibly even what types of cells the compounds will enter in the body. The different structures can also potentially prevent the development of drug resistance, as tumors that become resistant to one particular ruthenium drug structure could be vulnerable to another ruthenium compound with a different structure.

The efficacy of the compounds will be tested in different human cancer cell lines and in animal models to determine what cancer types can be treated. The group will also determine the biochemical process by which the compounds kill cells in order to optimize the drugs. The long-term goal of the research is to develop a targeted chemotherapeutic approach with reduced side effects that can be applied to a variety of cancer types.


'/>"/>

Contact: Allison Perry
allison.perry@uky.edu
859-323-2399
University of Kentucky
Source:Eurekalert

Related medicine news :

1. Loyola Cancer Center receives Outstanding Achievement Award
2. MU receives national award for using mind-body approach to improve health
3. Neuropsychologist receives University of Houstons highest faculty honor
4. Boston researcher, surgical oncologist receives national award
5. LA BioMed receives Grand Challenges Explorations grant
6. Lawson researcher receives 1 of first-ever Pfizer Psychiatry Research Awards
7. Dr. Arthur Slutsky, vice-president of research at St. Michaels, receives lifetime award
8. UC San Diego Superfund Research Program receives $15 million grant renewal
9. Markey receives $6.25 million to study deadly blood and bone marrow disease
10. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
11. UC Santa Barbaras Kavli Institute receives 2 grants to explore interface of physics and biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... , ... May 30, 2016 , ... ... 6th, while Shaolin warrior 8-day-8 and 8-night special intensive summer training camp starts ... annual overnight summer camp offers families and children a fun and unique experience ...
(Date:5/29/2016)... Cary, North Carolina (PRWEB) , ... May 29, 2016 , ... ... KP-400L wide jaw clipper that has been available via Amazon.com. This new ... who have thick nails. , The jaw opening is approximately 4mm and the actual ...
(Date:5/29/2016)... ... May 29, 2016 , ... "With 30 unique self-animating web themed ... the style of their project," said Christina Austin - CEO of Pixel Film Studios. ... created exclusively for use in Final Cut Pro X. Pixel Film Studios’ minimalistic titles ...
(Date:5/28/2016)... ... 2016 , ... "Color Grading media can be time consuming but with FCPX ... said Christina Austin - CEO of Pixel Film Studios. , With the FCPX ... color grades to their footage. A LUT is a Lookup Table that contains a ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the ... extraordinary event. The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 ... and the United Kingdom came together to explore the many pathways individuals use to get ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
(Date:5/25/2016)... 2016  According to Kalorama Information, the world ... 2015.  Though these are challenging times in the ... success for companies that remain optimistic and seek ... growth prospects medical device companies spend a higher ... (R&D) than do companies in other industries.  Also, ...
Breaking Medicine Technology: